Elevated circulating chemerin is associated with fetal endothelial dysfunction in GDM. Discordant mRNA/protein levels suggest post-transcriptional regulation. Cord blood chemerin may serve as a biomarker of fetal vascular injury, while fetal APV offers a non-invasive clinical tool. CMKLR1 antagonist studies are needed to establish therapeutic potential.
Zeng et al. (Wed,) studied this question.